End to plan for merger with Presidio follows BioCryst R&D setbacks
This article was originally published in Scrip
Executive Summary
BioCryst Pharmaceuticals and Presidio Pharmaceuticals announced merger plans on 18 October to create a company focused on orphan and infectious diseases, with a strong focus on hepatitis C virus (HCV). But before the month was through, the first of at least three negative events for BioCryst had put the pact in jeopardy, and by 30 November the companies terminated their proposed transaction.